Molecular Mechanisms of Inter-Organ Communication in Multimorbidity

Abstract

Multimorbidity, characterized by the coexistence of two or more chronic diseases in an individual, has become a major global health challenge, particularly due to the aging population. Recent research has unveiled that inter-organ communication via molecular signaling pathways plays a pivotal role in the pathogenesis and progression of multimorbid conditions. This review synthesizes current evidence on the molecular mechanisms facilitating crosstalk between organs, highlighting the clinical implications and emerging therapeutic avenues for managing multimorbidity.

Introduction

Multimorbidity poses significant diagnostic and therapeutic challenges for clinicians worldwide, given the complex interplay between distinct organ systems. Traditional disease management approaches often overlook the intricacies of inter-organ communication, underscoring the need for a mechanistic understanding at the molecular level. Recent advances in omics technologies and systems medicine have allowed for deeper insights into how molecular mediators such as cytokines, hormones, metabolites, and extracellular vesicles orchestrate pathophysiological processes across distant organs. This article explores these mechanisms in detail, aiming to inform clinical practice and research.

Epidemiology / Disease Burden

Globally, the prevalence of multimorbidity is rising, especially among older adults, with up to 70% of individuals over 65 years affected in some populations. The socioeconomic burden is immense, leading to increased healthcare utilization, polypharmacy, and decreased quality of life. Common clusters include cardiovascular-metabolic, neuropsychiatric, and musculoskeletal disorders. The recognition of molecular inter-organ crosstalk is crucial, as it may explain the frequent co-occurrence of specific disease patterns and guide more targeted interventions.

Pathophysiology

Inter-organ communication is orchestrated through multiple molecular networks. Cytokines such as IL-6, TNF-α, and TGF-β, released during chronic inflammation, can induce systemic effects, contributing to disease propagation from one organ to another. Endocrine mediators, including insulin and cortisol, modulate metabolic and immune responses, influencing distant tissues. Extracellular vesicles and microRNAs serve as carriers of genetic and protein information, mediating cellular responses and remodeling. The gut-liver-brain axis is a well-characterized example, where gut-derived metabolites and immune signals impact hepatic and neurological functions. These molecular exchanges can potentiate maladaptive responses, such as fibrosis, insulin resistance, or neurodegeneration, establishing a framework for multimorbidity development.

Risk Factors

Genetic predisposition, aging, lifestyle factors (sedentary behavior, poor diet, smoking), chronic stress, and environmental exposures are principal risk factors influencing the molecular networks underpinning inter-organ communication. Aging, in particular, is associated with immunosenescence and inflammaging, which drive aberrant cytokine production and systemic low-grade inflammation. Metabolic syndrome and obesity contribute via adipokine dysregulation, while chronic infections may incite persistent immune activation, further amplifying molecular crosstalk.

Clinical Features

The clinical presentation of multimorbidity is highly variable, often dominated by symptoms of the most advanced or symptomatic condition. However, systemic manifestations such as fatigue, cognitive decline, and sarcopenia may reflect underlying inter-organ molecular disturbances. The presence of one chronic disease (e.g., diabetes) can exacerbate or accelerate the onset of another (e.g., cardiovascular disease) through shared molecular pathways, complicating symptomatology and disease progression.

Diagnosis

Diagnosis of multimorbidity requires a comprehensive, patient-centered approach. Biomarkers reflecting systemic inflammation (CRP, IL-6), metabolic dysregulation (HbA1c, lipid panels), and organ-specific injury (troponins, NT-proBNP) are increasingly complemented by omics-based profiling (proteomics, metabolomics, transcriptomics). Advanced imaging and functional studies aid in assessing multi-organ involvement. Incorporating molecular insights may facilitate early detection of subclinical disease interactions and guide personalized care plans.

Treatment & Management

Effective management of multimorbidity necessitates integrated, multidisciplinary care. Addressing modifiable risk factors (diet, physical activity, smoking cessation) and optimizing control of primary conditions remain foundational. Polypharmacy should be carefully managed to minimize drug-drug interactions and adverse effects. Disease management strategies increasingly consider the molecular interconnections between conditions, such as targeting systemic inflammation or metabolic dysregulation, rather than focusing solely on organ-specific endpoints.

Recent Advances / Emerging Therapies

Recent years have seen the advent of targeted therapies modulating cytokine networks (e.g., IL-6 inhibitors in cardiovascular and autoimmune diseases), gut microbiota interventions to alter metabolite signaling, and the use of extracellular vesicles for diagnostic and therapeutic purposes. Systems biology approaches are being employed to map molecular networks and identify novel drug targets for multimorbidity. Personalized medicine, leveraging individual molecular profiles, is on the horizon, promising tailored interventions that address the unique inter-organ molecular landscape of each patient.

Guideline Recommendations

Several international guidelines now recommend a holistic, patient-centered approach to multimorbidity, emphasizing the importance of shared decision-making and individualized care plans. There is increasing advocacy for routine assessment of systemic inflammation and metabolic parameters, alongside traditional disease-specific metrics. The integration of molecular and omics data into clinical decision-making is encouraged, although practical implementation remains in early stages.

Conclusion

Understanding the molecular mechanisms of inter-organ communication has profound implications for the prevention, diagnosis, and management of multimorbidity. As evidence continues to unfold, clinicians must remain vigilant to the interconnected nature of chronic diseases, leveraging emerging molecular insights to optimize patient outcomes and embrace the promise of precision medicine in multimorbidity care.